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This review provides an overview of the current status of the global HIV pandemic
and strategies to bring it under control. It updates numerous preventive approaches
including behavioral interventions, male circumcision (MC), pre- and post-exposure
prophylaxis (PREP and PEP), vaccines, and microbicides. The manuscript summarizes
current anti-retroviral treatment options, their impact in the western world, and difficulties
faced by emerging and resource-limited nations in providing and maintaining appropriate
treatment regimens. Current clinical and pre-clinical approaches toward a cure for HIV are
described, including new drug compounds that target viral reservoirs and gene therapy
approaches aimed at altering susceptibility to HIV infection. Recent progress in vaccine
development is summarized, including novel approaches and new discoveries.
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INTRODUCTION
Beginning with the FDA approval of AZT in 1987 for HIV treat-
ment and the subsequent development of combination therapies,
millions of HIV infected people have been saved from progres-
sion to AIDS, and their quality of life has improved dramatically
(Broder, 2010). An outgrowth of the successful advances in AIDS
treatment regimens is the recent finding that early initiation of
antiretroviral therapy (ART) can reduce HIV transmission by
96% (Cohen et al., 2011). Moreover, mother-to-child transmis-
sion can be prevented using anti-HIV drugs, as recently reviewed
for low- and middle-income countries (Siegfried et al., 2011;
Tudor Car et al., 2011; Santos et al., 2012). The challenges of
implementing such “treatment as prevention” strategies aremany,
however, as reviewed here. Overall, in addition to pursuing new
developments in treatment, all available preventive measures as
well as continued research efforts toward an efficacious HIV vac-
cine should be employed to effectively control the HIV/AIDS
pandemic.
FACTS AND FINANCES: THE GLOBAL CHALLENGE OF
HIV INFECTION
Human immunodeficiency virus (HIV) infection and the incur-
able disease, acquired immunodeficiency syndrome (AIDS),
present major global health problems. Approximately 34 million
people worldwide are currently living with HIV, 1–1.2 million of
these in the United States (Table 1). The overall US HIV infec-
tion rate has remained steady since the 1990s with around 49,000
cases per year, the majority in men having sex with men (MSM)
(Moore, 2011; Morris and Little, 2011; Prejean et al., 2011).
Moreover, the global HIV prevalence is expected to increase
within the next 10 years (Yehia and Frank, 2011), indicating that
action on a national and international level is needed. The cur-
rent standard of care is ART which requires daily medication
to prevent disease progression and re-emergence of the virus.
However, co-infection of HIV infected patients with tuberculo-
sis or hepatitis as well as sexually transmitted diseases, together
with problems in health care systems and infrastructure, have an
impact on treatment success (Beauliere et al., 2010; Obiako and
Muktar, 2010; Birbeck et al., 2011; Boesecke and Vogel, 2011;
Finlayson et al., 2011).
ART is expensive as illustrated by costs in the US that aver-
age $30,000/year/patient and are similarly high in European
countries (Table 1) (Fleishman et al., 2010; Gebo et al., 2010;
Colombo et al., 2011; Hill et al., 2011; Krentz and Gill, 2012).
Despite multi-tier pricing models (Wirtz et al., 2009), global
costs for treatment are high (Table 1) and current predictions
call for over 1.7 billion dollars per year to fight HIV in low-
and middle-income countries (Nunn et al., 2007; Stover et al.,
2011). Moreover, the future of outside funding for treatment
(e.g., PEPFAR, the President’s Emergency Plan for AIDS Relief)
under current global economic conditions is tenuous, as a drop in
funding due to the weakened global economy has been reported
with consequences for programs and patients in Africa (Voelker,
2011; Wasswa, 2011). Worldwide, treatment costs impact fami-
lies, economies and health care systems. In the US alone, therapy
for STDs and HIV cost from 14 to 23 billion dollars a year
(Chesson et al., 2011). HIV/AIDS is associated with poverty,
lower education and minority populations (Torrone et al., 2010;
Vermund et al., 2010; Dang et al., 2011; Espinoza et al., 2012).
Only 15–17% people living with HIV have private insurance and
nearly 30% in the US do not have any coverage (Espinoza et al.,
2012; http://healthcare.gov/news/factsheets/affordable_care_act_
people_hiv_aids.html). Since up to 21% of these groups would
likely be starting treatment in an advanced disease state due
to unawareness, late detection of infection (Moore, 2011; Yehia
and Frank, 2011; Espinoza et al., 2012) or being undocumented
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Table 1 | HIV/AIDS: facts and finance.
Prevalence Currently HIV infected Newly infected (2010) AIDS deaths References
US 1.2 million 49 thousand 17 thousand (2009) Prejean et al., 2011, 1
Global 34 million 2.7 million 1.8 million (2010) 2
Treatment costs Per person/year Currently infected/year Newly infected/year
US $10–$60 thousand $14–$23 billiona $1.47 billionb Fleishman et al., 2010; Gebo
et al., 2010; Chesson et al.,
2011; Hill et al., 2011; Krentz
and Gill, 2012
Treatment through the
global AIDS fund
First line ART: $487,
second line ART: $1521
3.5 million people treated
(2011): ∼$1.9 billion
– Stover et al., 2011
aEstimated cost for treatment of STDs and HIV.
bEstimated using $30,000 per person, per year.
1. http://www.cdc.gov/hiv/resources.factsheets/us.htm
2. http://www.who.int/hiv/data/2011_epi_core_en.png
(Dang et al., 2011), costs for therapy would be higher. Measures
to prevent HIV infection at the outset would provide a significant
financial benefit by lowering health care costs. Overall, finding
measures to prevent HIV infection or affect a cure are of highest
importance for the broadest benefit to public health (Long and
Owens, 2011).
WORLDWIDE IMPLEMENTATION OF ART
Effective treatment enables HIV infected individuals to be pro-
ductive members of society, a critical economic benefit (Resch
et al., 2011). However, making treatment worldwide readily avail-
able is a challenge. Aside from high costs (Table 1), successful ini-
tiation and maintenance of AIDS therapy in emerging countries
and the developing world can be limited by political and sociolog-
ical factors including instability of governments and health care
systems, transportation problems and poor nutrition (Beauliere
et al., 2010; Obiako and Muktar, 2010; Birbeck et al., 2011). If
disease is diagnosed late as often occurs in developing coun-
tries, treatment success can be diminished due to late stage AIDS,
HIV-associated dementia and opportunistic infection requiring
additional, often unavailable, treatment. Social barriers such as
personal and family shame or blame and societal stigma, often
paired with insufficient education on HIV/AIDS, can also pre-
vent individuals from seeking treatment (Amuri et al., 2011; Dang
et al., 2011; Winskell et al., 2011; Espinoza et al., 2012; Steward
et al., 2012).
The overall benefits outweigh by far the side effects of ART
medications. However, in the course of treatment new prob-
lems surface and medical care has to be adjusted accordingly
(Llibre et al., 2009) which can be difficult in the developing
world. ART can induce immune reconstitution inflammatory
syndrome upon initiation, making the monitoring of CD4 T-
cells, viral load, liver, and kidney function crucial for successful
treatment (Kalyesubula and Perazella, 2011; Keiser et al., 2011;
Barber et al., 2012). Further, there is a tendency for HIV infected
patients on ART to show increased kidney damage in addi-
tion to HIV associated nephropathy and cardiovascular disease.
An increased risk for myocardial infarct has been attributed to
the protease inhibitors lopinavir/ritonavir and the transcriptase
inhibitor abacavir (Fichtenbaum, 2010; Islam et al., 2012a,b;
Maggi et al., 2012). Markers of systemic inflammation (c-reactive
protein, IL-6), coagulation, and renal function are elevated in
HIV infected patients independent of successful suppression of
viremia (Neuhaus et al., 2011; Bastard et al., 2012). The elevated
inflammatory markers can indicate ongoing low level viral repli-
cation in tissues only minimally reached by ART and subsequent
cell-to-cell viral spread, as ART does not completely reverse T-cell
activation (D’Ettorre et al., 2011). In addition to T-cell activation,
B-cell abnormalities and loss of memory B-cells persist despite
long-term treatment with ART (Chong et al., 2004; Moir and
Fauci, 2009). B-cell lymphomas and other cancers (e.g., squa-
mous cell carcinoma) are increasing in HIV infected patients
(Carbone et al., 2009; Epeldegui et al., 2010; Gervaz et al., 2011;
Tyerman and Aboulafia, 2012) requiring additional treatment.
First line combination therapy, consisting of one non-
nucleoside reverse transcriptase inhibitor (NNRTI) and two
nucleoside reverse transcriptase inhibitors (NRTI) as recom-
mended by theWHO, is often the only available form of treatment
in low-income countries (www.who.int/hiv/pub/arv/adult2010/
en/index.html). As of December, 2010, in 45 low- and middle-
income countries excluding the Americas, of the 81% of patients
receiving treatment, 97% were on first-line regimens (>54%
on Nevirapine, Lamivudine and Stavudine, or Zidovudine) and
only 2.9% on significantly more costly second line treatment
regimens (www.who.int/hiv/pub/progress_report2011/en/). As a
result, this can lead to the emergence of viral resistance to first
line treatment. To combat this problem, frequent monitoring of
viral loads and strict treatment adherence to the drug regimen
are important, but can be problematic (Birbeck et al., 2011). Over
time despite treatment adherence and maintenance of viral load
suppression, resistance develops in about 30% of patients. Not
only does this result in treatment failure, the resistant viruses can
be transmitted, cause new infections that are not controlled by
the existing drug regimen (Hamilton et al., 2012; von Wyl et al.,
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2011), and jeopardize future treatment options (Chamberland
et al., 2011). Especially, concerning is the frequency of viral resis-
tance to first-line ART that arises among children in resource
poor countries (Sigaloff et al., 2011). Resistance mutations vary
depending on the type of drug regimen. However, regardless of
the mechanism, resistance to ART develops inexorably, showing
the urgent need not only for new treatments but also alternative
preventive measures.
ADDITIONAL APPROACHES TO PREVENT INFECTION
In spite of the dramatic reports of preventing HIV transmission
using early ART, other studies have suggested that testing and
early treatment alone might not significantly reduce HIV trans-
mission in the near future, as predicted by a study in Washington,
DC (Walensky et al., 2010), a current “hot-spot” of HIV infec-
tion (Greenberg et al., 2009; Carr et al., 2010; Hanna et al., 2011).
To be prudent, additional measures, of which there are several,
would enhance the likelihood of successful prevention. Among
the easiest is syringe and needle exchange programs. HIV is most
commonly transmitted by sexual contact. However, transmission
also occurs among intravenous drug users (IDU) via needle and
syringe sharing (Nacopoulos et al., 2010; Vlahov et al., 2010).
In the US approximately 12% of all new HIV infections per
year occur in IDU (Adimora and Auerbach, 2010). Syringe and
needle exchange programs provide a simple, inexpensive preven-
tive measure in this population (Adimora and Auerbach, 2010;
Nacopoulos et al., 2010; Vlahov et al., 2010).
Sexual transmission of HIV is best prevented by practic-
ing safe sex or abstinence, both confounded by multifaceted
behaviors. Failure to practice safe sex may be due to lack of
knowledge about HIV infection and treatment, and perhaps
the assumption that ART cures HIV (Owoaje et al., 2011;
Smith et al., 2011). Other factors include gender inequity of
woman, particularly in negotiating condom use, and partner
violence (Jewkes et al., 2010; East et al., 2011; El-Bassel et al.,
2011; Fair and Vanyur, 2011; Gakumo et al., 2011; Swan and
O’Connell, 2011). Additionally, alcohol and substance abuse
influence personality traits and risk behavior, and lower the
frequency and ability to negotiate condom use (Tapert et al.,
2001; Kogan et al., 2010; Finlayson et al., 2011; Hagger-Johnson
et al., 2011; Maisto et al., 2012; Rehm et al., 2012). Selected
clinical trials that address behavioral modification are listed
in Table 2. Behavioral modification is difficult, however, and
mixed results have been obtained. Of five investigated inter-
ventions (billboards, peer education, magazines, radio broad-
casts, and public outreach events) the latter three were signif-
icantly correlated with increased condom use, but the over-
all influence on behavior was limited (Hsu et al., 2012). In
another study, behavioral interventions among 725 HIV-positive
women had no effect on increased condom use (Carvalho
et al., 2011). Behavioral interventions in the workplace, includ-
ing voluntary counseling and testing to reduce risky sexual
behavior, found no reduction in HIV incidence rate or fre-
quency of unprotected sex, although, education did reduce
unprotected sex, STDs and sex with commercial sex workers
(Ojo et al., 2011).
To augment safe sex practices and abstinence, oral/systemic
pre-exposure prophylaxis (PREP) has been shown effective in
preventing HIV infection both in non-human primates and
humans (Tsai et al., 1994a,b; Grant et al., 2010; Myers andMayer,
Table 2 | Selected clinical trials targeting behavior modification as a measure to prevent HIV infection.
Behavioral
intervention/counseling
Status Phase Target group Alternate
study ID
Approach References
NCT00000931 Complete III MSM HIVNET 015
EXPLORE
Behavioral intervention Koblin et al., 2004;
(IIB trial results)
NCT00710060 Complete III At-risk
populations
DAHBR
9A-ASGT
Community-level prevention
program
Rotheram-Borus
et al., 2011
NCT00729391 Active III Women R01HD058320 Voluntary counseling and
testing; equal attention control
group
–
NCT00859144 Not yet
recruiting
III Urban youth CHAMPions,
DAHBR
9A-ASPA
Behavioral intervention: be
proud! be responsible!,
becoming a responsible teen
(BART)
–
NCT00279799 Unknown III African American
females (age
14–20)
816-2003 AFIYA HIV prevention
intervention
–
NCT00310973 Complete II/III MSM DAHBR
9A-ASPG
Educational counseling Kelly et al., 2006
NCT01152281 Recruiting II/III At risk
populations
Selective
exposure
Meta-intervention to increase
retention in prevention
counseling
–
More information about the individual trials can be found using the NCT number and the following databases: www.aidsinfo.nih.gov/clinical-trials;
www.clinicaltrials.gov; http://www.avac.org.
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2011). It must be used consciously and before sexual activity in
order to achieve a sufficient inhibitor concentration. Reduction
in HIV acquisition is dependent on adherence to PREP use and
ranges from 21 to 73% (Krakower and Mayer, 2011; Naswa and
Marfatia, 2011). Factors associated with PREP failure are similar
to those of condom use, including failure to have the medication
on hand and adherence (Golub et al., 2010; van der Straten et al.,
2012). Questions concerning the implementation of PREP and
guidelines for its use are both scientific (e.g., oral vs. mucosal) and
policy related (e.g., insurance coverage of treatment expenses)
(Myers and Mayer, 2011; Naswa and Marfatia, 2011). Current
cost estimates for PREP for 100,000 high risk persons in the US
are over $1 billion a year ($900 in medication costs per month)
(Leibowitz et al., 2011), making the implementation of PREP
in tough economic times unlikely despite potential long-term
benefits (Koppenhaver et al., 2011). Further, emergence of drug
resistance is a potential pitfall for PREP users but might have only
a negligible impact as shown for MSM in the UK (Dolling et al.,
2011).
Post-exposure prophylaxis (PEP) or post-exposure pro-
phylaxis following sexual exposure (PEPSE) must be used
conscientiously and requires a long follow up interval of up to
6months post-exposure as recommended by the CDC (www.cdc.
gov/mmwr/preview/mmwrhtml/rr5402a1.htm) (McCarty et al.,
2011). PEPSE awareness in high risk groups has increased sig-
nificantly, but its use in general is low (Zablotska et al., 2011).
However, PEP after accidental exposure (e.g., needle stick injury)
or for victims of sexual assault and rape has a proven track record
of preventing infection. As for PREP, timing is critical. Treatment
should not be delayed more than 72 h post exposure without a
significant chance of infection. Table 3 lists selected clinical tri-
als for PREP and PEP. For further information on PREP and
PEP methods, strategies, costs, etc. see Fernandez-Montero et al.
(2012).
Microbicide development for HIV prophylaxis is another
active area of research. A number of microbicide candidates have
been tested in clinical trials (Table 4), but few have shown effi-
cacy, and some have possibly enhanced HIV acquisition (Tao
et al., 2008; Abdool Karim et al., 2010, 2011; Pirrone et al.,
2011, 2012). The gel base for microbicides must be chosen cau-
tiously, as some can cause epithelial damage facilitating HIV
infection (Begay et al., 2011). The latest microbicides containing
Table 3 | Selected clinical trials investigating PrEP and PEP for prevention of HIV infection.
Trial
identifier
Status Phase Target group Alternate
study ID
Component Comment/
references
PrEP
NCT00458393 Active III MSM Peru PrEP,
iPREX
Emtricitabine/tenofovir
disoproxil fumarate
44% efficacy; Grant
et al., 2010
NCT00931346 Complete I/II HIV discordant
couples
IAVI E002 Emtricitabine/tenofovir
disoproxil fumarate
–
NCT00557245 Active III HIV discordant
couples
32528-A, IND
75,365
Emtricitabine/tenofovir
disoproxil fumarate
–
NCT01473472 Not yet
recruiting
III MSM IPERGAY Emtricitabine and
tenofovir disoproxil
fumarate (truvada)
–
NCT01275443 Recruiting I People at risk for
HIV
SSAT 040 TMC278 (rilpivirine),
long-acting
formulation
–
PEP
NCT00594646 Complete IV High-risk sexual
contact
MK PEP 2007 Fixed-dose tenofovir
and raltegravir
–
NCT00385645 Complete IV Accidental HIV
exposure
DATEM-PEP AZT-3TC +
lopinavir-ritonavir vs.
ZT-3TC + atazanavir
–
NCT01140880 Recruiting II MSM MC08-LA-710-
FRI
Emtricitabine and
tenofovir disoproxil
fumarate (truvada)
–
NCT00949234 Recruiting II High-risk sexual
contact
PQUAD Tenofovir +
emtricitabine,
lopinavir/ritonavir
–
NCT01087840 Recruiting IV MSM RAL-NPEP Raltegravir –
More information about the individual trials can be found using the NCT number and the following databases: www.aidsinfo.nih.gov/clinical-trials;
www.clinicaltrials.gov; http://www.avac.org.
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Table 4 | Selected clinical trials of microbicides.
Microbicides Status Phase Type of
prevention
Alternate
study ID
Component Comment/
references
NCT00262106 Complete III Gel, vaginal MDP301,
ISRCTN64716212
PRO 2000/5 gel
0.5% and 2%
Not efficacious;
McCormack
et al., 2010
NCT00153777 Terminated III Gel, vaginal CONRAD,
C03-090
Cellulose sulfate
gel (6%)
No protection,
possible
enhancement;
Van Damme
et al., 2008
NCT00213083 Unknown III Gel, vaginal Population
council #322
Carraguard
(PC-515)
No protection;
Skoler-Karpoff
et al., 2008
NCT00441298 Complete II Gel, vaginal CAPRISA 004 Tenofovir 1% gel 39% efficacy;
Abdool Karim
et al., 2010
NCT00705679 Active II Gel, vaginal
and ART
oral
VOICE,
MTN-003
Tenofovir 1%
vaginal gel,
emtric-
itabine/tenofovir
disoproxil
fumarate
Vaginal gel arm
halted, no
efficacy; 1
NCT00740584 Complete I/II Gel, vaginal SPL7013-003,
DAIDS ES
number
10730
3% SPL7013 gel
(VivaGel)
Price et al., 2011
NCT00850837 Recruiting I Gel, vaginal AF 020 Acidform
lubricant
(Amphora)
–
NCT01283360 Recruiting I Gel, rectal CONRAD,
1009001
Tenofovir 1% gel –
More information about the individual trials can be found using the NCT number and the following databases: www.aidsinfo.nih.gov/clinical-trials;
www.clinicaltrials.gov; http://www.avac.org.
1. http://www.niaid.nih.gov/news/newsreleases/2011/Pages/VOICEdiscontinued.aspx
Tenofovir, a reverse transcriptase inhibitor, have shown promis-
ing but modest efficacy, as in the CAPRISA trial (Abdool Karim
et al., 2010). However, a recent clinical trial (VOICE, MTN-003)
evaluating daily use of a vaginal gel containing Tenofovir in
over 5000 woman was discontinued, as interim analysis showed
no difference in HIV incidence rate compared to use of a
placebo gel (Table 4). Among new approaches, evaluation of
topical 2-Hydroxypropyl-beta-cyclodextrin has shown promise
in an animal model (Ambrose et al., 2008), as have live lacto-
bacilli engineered to secrete cyanovirin (Lagenaur et al., 2011).
The latter approach if successful might alleviate problems of
adherence by reducing the need for application just prior sex-
ual exposure. In the Carraguard trial self-reported microbicide
use was 96%, but applicator testing revealed actual adherence
was only 42% (Skoler-Karpoff et al., 2008). Microbicides under
development are incorporating other ART components such as
integrase, protease or reverse transcriptase inhibitors. Antibodies
are also being considered (Selhorst et al., 2011). A major draw-
back of current microbicide clinical trials is that efficacy is
only tested in heterosexual woman, not in high risk MSM
where the majority of new infections occur in the US (Abdool
Karim et al., 2010; Krakower and Mayer, 2011; Prejean et al.,
2011).
Male circumcision (MC) has been recognized fairly recently
as a potential preventive measure, but its overall impact may
depend on the target population. Multiple trials in Africa have
shown efficacy of MC in reducing HIV acquisition in hetero-
sexual men by 38–66%, with uncircumcised men showing an
4-fold higher infection risk in sub-Saharan Africa (Siegfried
et al., 2009; Gebremedhin, 2010; Wamai et al., 2011) (Table 5).
However, the impact of MC for MSM is unknown (Smith
et al., 2010), as is the overall population of MSM in sub-
Saharan Africa. It has been estimated that HIV transmission
among MSM accounts for 0.6–16% of infections, depending
on the country (Wamai et al., 2011). Newer data suggest that
MC among MSM in the US, where the overall prevalence of
MC already ranges from 43 to 80%, would be of limited ben-
efit (Gust et al., 2010; Jozkowski et al., 2010; Smith et al.,
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Table 5 | Selected clinical trials of male circumcision.
Male
circumcision
Status Phase Target
group
Alternate
study ID
Observation References
NCT00124878 Unknown III Men 22006 No reduction of HIV
transmission to
female partners
Wamai et al.,
2011
NCT00425984 Complete III Men U1AI171-1-02 55% efficacy Gray et al., 2007
NCT00122525 Terminated III Men ANRS 1265 60% efficacy Auvert et al.,
2005
More information about the individual trials can be found using the NCT number and the following databases: www.aidsinfo.nih.gov/clinical-trials;
www.clinicaltrials.gov; http://www.avac.org.
2010; Wei et al., 2011). A protective effect was seen in a sub-
group of MSM reporting an insertive role, but overall, in 21
observational studies with 71,693 MSM participants, MC did
not prevent HIV transmission (Wiysonge et al., 2011), probably
because it has no effect on transmission through receptive anal
intercourse.
Other alternatives for prevention or cure are targeting the
CCR5 receptor as well as the latent HIV reservoir. With regard
to the former, the idea of modulating the expression of CCR5
on CD4 T-cells is not new and CCR5 blocking molecules are
used in the clinic (e.g., Maraviroc) or have been investigated
in animal models or clinical trials (e.g., TAK-779, Aplaviroc,
and Vicriviroc). However, resistance, lack of efficiency or tox-
icity has been associated with these compounds (Ryan, 2005;
Sax, 2006; Nichols et al., 2008; Ogert et al., 2008; Demarest
et al., 2009; Kitrinos et al., 2009; Wilkin et al., 2010). For
example, treatment with CCR5 co-receptor antagonists can lead
to selection of resistant viruses whose entry rates into target
cells in the presence of the antagonist have been restored to
wild-type levels (Putcharoen et al., 2011). Nevertheless, inter-
est in targeting the CCR5 co-receptor persists, in part due to
the case study of an individual potentially cured of HIV infec-
tion after receiving a bone marrow transplant for treatment of
acute myeloid leukemia from a donor homozygous for CCR532
(Allers et al., 2011). New approaches include attempts to per-
manently alter the expression of the CCR5 receptor on CD4
cells by gene therapy (e.g., knockout and knockdown) (Cannon
and June, 2011). shRNA knockdown of CCR5 in the humanized
mouse model has led to reduced expression on T-cells in the gut
mucosa, and splenocytes were harder to infect with HIV (Shimizu
et al., 2010). In another experiment, RNA interference-mediated
knockdown of CCR5 was stable for 10 days and challenged
animals exhibited reduced plasma viral loads and enhanced resis-
tance to infection (Kim et al., 2010). Nevertheless, all interven-
tions have drawbacks. Disadvantages of CCR5 knockout include
lower anti-tumor, anti-bacterial and anti-parasitic responses, as
shown in animal model studies (Gonzalez-Martin et al., 2011;
Olive et al., 2011; Sullivan et al., 2011). In addition, disruptions
of the normal control of other infectious diseases may occur. For
example, in humans CCR5 deficiency is a risk factor for both
early and late clinical manifestations of West Nile virus (Lim
et al., 2010) and tickborne encephalitis (Kindberg et al., 2008)
infections.
The idea of purging the viral reservoir in order to affect a cure
of HIV infection has been a long-term goal (Frater, 2011; Palmer
et al., 2011). However, simply intensifying drug regimens has not
succeeded despite suppression of viral loads below 1 copy/ml
plasma (Byakwaga et al., 2011; Dahl et al., 2011). A potential
explanation could be on going cell to cell spread of the virus
(Sigal et al., 2011). In rare instances upon infection of resting
CD4T-cells HIV goes into latency, a phenomenon known for over
20 years (Bednarik and Folks, 1992). These latent reservoir cells
have a long half-life and reactivation leads to reemerging viremia
(Iglesias-Ussel and Romerio, 2011; Pace et al., 2011). Mechanisms
controlling latency act at the transcriptional level, where hypo-
acetylation of histones correlates with repression (Lafeuillade and
Stevenson, 2011). Histone deacetylase (HDAC) inhibitors, such
as Valproic acid (VPA), a known medication for psychiatric dis-
orders, have been tried together with ART to reduce the latent
virus reservoir with mixed results and side-effects at higher doses
(Lehrman et al., 2005; Margolis, 2011; Matalon et al., 2011; Routy
et al., 2012). The development of safer, more efficient HDAC
inhibitors in combination with ART might provide a promising
path toward a cure for HIV (Margolis, 2011). Other more spe-
cific HDAC inhibitors are under development (Matalon et al.,
2011). A promising candidate is Givinostat, shown to be safe in
humans, and slated to move into clinical phase II trials (Furlan
et al., 2011).
VACCINE DEVELOPMENT
HIV vaccines have been designed for both therapy and preven-
tion. Multiple clinical trials with therapeutic vaccines have been
conducted. To mention a few, approaches have included rAd5-
HIV gag (Li et al., 2011) Tat protein or Tat DNA (Caputo et al.,
2009), ALVAC encoding multiple HIV genes plus gp160 (Jin et al.,
2002), gp160 protein alone (Kundu-Raychaudhuri et al., 2001;
Gudmundsdotter et al., 2008), and dendritic cells (DC) pulsed
with autologous inactivated virus (García et al., 2011). The overall
outcome in most studies was a temporary significant drop in viral
loads, induction of cytotoxic T-cell responses, as well as improved
CD4 counts. To date, therapeutic vaccines have not progressed
to the point of replacing drug therapy. However, this is an impor-
tant although challenging goal in view of toxicities associated with
drug regimens. A key factor in application of all therapeutic vac-
cines may be early initiation after infection in order to surmount
HIV-associated T- and B-cell dysfunctions.
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Most of the research emphasis in the field is devoted toward
the development of a preventive HIV vaccine. A highly effica-
cious vaccine would circumvent the need for multiple preven-
tive strategies, and would have its greatest impact in countries
of the emerging and developing world where treatment avail-
ability is still scarce. However, such a vaccine is still elusive
(Girard et al., 2011). The clinical trial (RV144) of ALVAC-
HIV recombinant priming followed by gp120 protein boosting
(Table 6) (Rerks-Ngarm et al., 2009; Girard et al., 2011) con-
ducted in Thailand showed 31% efficacy. It has been suggested
that in Thailand the RV-144 approach could provide modest
long term benefit even without revaccination to combat the
short-term effectiveness of the vaccine (Schneider et al., 2011).
However, the vaccine approach overall was far from reaching
the protective efficacy desired. As outlined below, achieving a
more efficacious vaccine will require continuing, major research
efforts.
An ideal vaccine should induce long lived memory T-cells
with high cytotoxic potential and B-cells able to secrete potent,
functional antibodies (Benmira et al., 2010). As T-cell vaccines
have been intensively reviewed recently (Ahlers and Belyakov,
2010a,b; Perrin et al., 2010), here we will address B cell immu-
nity. That antibodies alone are sufficient to prevent infection has
been clearly shown in passive transfer studies in animal mod-
els (Baba et al., 2000; Mascola et al., 2000; Nishimura et al.,
2003). Additionally, a recent gene therapy approach using an
AAV vector expressing neutralizing antibody conferred protec-
tion in non-human primates (Johnson et al., 2009). In addition
to the well-known broadly neutralizing antibodies b12, 2G12,
2F5, 4E10, and Z13 (Muster et al., 1993; Burton et al., 1994;
Trkola et al., 1996; Zwick et al., 2001) the recent isolation of
even more potent broadly neutralizing antibodies from infected
patients, including VRC-01, -02, and -03; PG9, PG16, 3BNC117,
NIH45-46, PGT121-123, and PGT125-128 (Walker et al., 2009,
2011; Wu et al., 2010; Scheid et al., 2011), shows that the immune
system is capable of producing these highly sought antibodies.
However, no vaccine approach has been able to elicit them, due
in part to the complex structure of the HIV (and SIV) envelope
Table 6 | Selected clinical trials of HIV prophylactic vaccines.
Clinical trial
identifier
Status Phase Vaccine approach Alternative
study ID
Vaccine components Comment/
references
NCT00002441 Complete III Subunit priming and
boosting
AIDSVAX B/B,
VAX 004
MN rgp120/HIV-1 and
GNE8 rgp120/HIV-1
No protection;
Flynn et al., 2005
NCT00006327 Complete III Subunit priming and
boosting
AIDSVAX B/E,
VAX 003
MN rgp120/HIV-1 and
A244 rgp120/HIV-1
No protection;
Pitisuttithum
et al., 2006
NCT00223080 Active III Vector priming,
subunit boosting
RV-144 ALVAC-HIV vCP1521 +
AIDSVAX
31.2% efficacy;
Rerks-Ngarm
et al., 2009
NCT00095576 Terminated II Vector priming and
boosting
STEP study Trivalent MRKAd5 HIV-1
gag/pol/nef
No protection;
Buchbinder et al.,
2008
NCT00413725 Suspended II Vector priming and
boosting
Phambili study MRKAd5 HIV-1
gag/pol/nef
No protection;
Gray et al., 2011
NCT00865566 Recruiting II DNA priming, vector
boosting
HVTN 505 VRC-HIVDNA016-00-VP
(DNA) +
VRC-HIVADV014-00-VP
(rAd5)
–
NCT00820846 Active II DNA priming, vector
boosting
HVTN 205 pGA2/JS7 DNA + MVA
/HIV clade B gag-pol-env
–
NCT01418235 Recruiting I DNA/vector/subunit HVTN
086/SAAVI 103
DNA-C2 + MVA-C +
gp140 in MF59
–
NCT00062530 Not yet
recruiting
I Recombinant
bacteria
P01AI47490 Oral recombinant
Salmonella typhi HIV-1
gp120
–
NCT01441193 Recruiting I Subunit priming and
boosting
ISS P-002 HIV-1 Tat; delta-V2 Env –
NCT01095224 Recruiting I Vector priming and
boosting
HVTN 083 rAd35 Env A+rAd5 Env
A or rAd5 Env B
–
More information about the individual trials can be found using the NCT number and the following databases: www.aidsinfo.nih.gov/clinical-trials;
www.clinicaltrials.gov; http://www.avac.org.
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(Roux and Taylor, 2007; Schief et al., 2009; Harris et al., 2011;
White et al., 2011). Additionally, the HIV envelope has shown
poor binding to germline predecessors of broadly neutralizing
antibodies, suggesting a mechanism by which HIV may evade
immune responses (Xiao et al., 2009; Chen et al., 2012). In
fact, although examination of VRC-01-like antibodies revealed
a common pathway of maturation, extensive affinity matura-
tion steps were required to attain broad reactivity (Zhou et al.,
2010; Scheid et al., 2011; Wu et al., 2011). Overall, up to 30%
of HIV infected individuals develop cross-reactive neutralizing
antibodies approximately 3 years after seroconversion, suggesting
that the antibodies need multiple rounds of somatic hypermu-
tation and affinity maturation to achieve broad reactivity and
that current recombinant envelope immunogens are unable to
promote this process from precursor naïve B-cells (Euler et al.,
2012).
Reverse vaccinology and structure-based vaccine design
approaches focused on known neutralizing antibody targeted
envelope epitopes are attempting to develop vaccine immuno-
gens able to elicit the desired neutralizing antibody potency
and breadth (Pejchal and Wilson, 2010; Walker and Burton,
2010). One approach to achieve presentation of critical confor-
mational epitopes is stabilization of the CD4-mediated confor-
mational change in the envelope using a single-chain analogue
of the HIV gp120-CD4 complex (DeVico et al., 2007). Other
approaches as reviewed in Kwong et al. (2011) and Walker
and Burton (2010) include virus like particles, soluble trimers,
stabilized envelope trimers with deletion of the gp41 trans-
membrane domain, conformational stabilization of the Env core
protein, generation of envelope subdomains (e.g., the outer
domain containing the CD4 attachment site), and employment
of scaffolds based on informatics and epitope transplantation
(e.g., adding the conserved β15 loop of the CD4 binding site
to an unrelated structure to present the epitope in its natural
configuration). Stable trimers are now available and maintain
native conformation (Harris et al., 2011; Lewis et al., 2011;
Sellhorn et al., 2011). However, overall envelope glycosylation
and the resulting glycan shield can still influence immunogenic-
ity (Benjouad et al., 1992; Kumar et al., 2011) and remains
a problem for vaccine development and design (Kwong et al.,
2011).
The variable loop regions (V1/V2 and V3) of the viral envelope
have regained attention, due to their interaction with the gut-
homing α4β7 receptor (Arthos et al., 2008), role in viral trans-
mission, binding to highly potent neutralizing antibodies (Doores
and Burton, 2010; Collins-Fairclough et al., 2011; Pejchal et al.,
2011) and recent correlation with reduced risk of HIV infection
in the RV144 trial (Zolla-Pazner et al., 2011a). As a result, scaf-
folds that present V1-V2 in the appropriate native conformation
are currently under study. However, during HIV infection, V1-V2
loop sequences expand and add glycosylation sites, which in turn
could affect binding and neutralization by antibodies (Sagar et al.,
2006). The V3 loop, long-thought to elicit only type-specific anti-
bodies, has some structurally conserved elements (Carrow et al.,
1991; Boudet et al., 1992; Almond et al., 2010; Jiang et al., 2010),
suggesting a potential for inducing broadly neutralizing antibod-
ies. Recently, a V3 scaffold immunogen based on structure-guided
design elicited cross-clade neutralizing antibodies in rabbits
(Totrov et al., 2010; Zolla-Pazner et al., 2011b), raising hope
that similar constructs would be equally effective in humans.
Nevertheless, structural approaches and reverse engineering still
face multiple obstacles and limitations from numerous extrin-
sic factors such as the host immunoglobulin gene repertoire
and cellular regulatory mechanisms in the immunized host dur-
ing antigen processing and antibody affinity maturation (Van
Regenmortel, 2011, 2012). Additional limitations are imposed by
discontinuous epitopes that are difficult to isolate in their native
tertiary structure, and quaternary structure which introduces
transient, conformational “neotopes” and masked “cryptotopes”
which appear only in the context of the assembled virus particle
(Van Regenmortel, 2011, 2012). Cross-reactivity or heterospeci-
ficity arising from weak antigen B-cell receptor interactions can
also potentially lead to auto reactive antibodies as reported for
2F5 and 4E10 (Haynes et al., 2005). Understanding the complex
interactions between antigen presenting cells (APC) and B-cells at
different mucosal sites or in lymph nodes is important for design-
ing optimal vaccine approaches. The HIV envelope in particular
is poorly immunogenic. It can suppress CD4 T-cell activation
and proliferation (Fernando et al., 2007) and can mediate T-cell
apoptosis (Arthos et al., 2002). Further, high affinity antibod-
ies recognizing the CD4-binding site can skew MHC class II
presentation by partially obstructing antigen processing, leading
to decreased anti-gp120 T helper responses (Tuen et al., 2005).
It is crucial to find measures to boost the envelope’s immuno-
genicity in order to elicit potent and durable anti-env responses.
The contributions of cells of the innate immune system, such
as NK, NKT, γδ T-cells, and DC are under extensive investi-
gation (Bostik et al., 2010; Palucka et al., 2010; Agrati et al.,
2011; Altfeld et al., 2011; Padte et al., 2011; Ansari et al., 2012).
Cross-talk between the innate and adaptive immune systems is
important in shaping adaptive B-cell responses (Cerutti et al.,
2011). Innate programming of protective immunity in general
and programming of antibody (and T cell) responses by innate
immune components have recently been reviewed (Pulendran
and Ahmed, 2011).
Apart from design of specific vaccine components and regi-
mens, the route of administration can influence immune response
elicitation, systemically and mucosally at genital/rectal sites
(Demberg and Robert-Guroff, 2009; Mestecky et al., 2010).
Vectored vaccines can be administered by a variety of routes
and in addition to eliciting T cell responses also effectively
induce humoral immunity. Prominent vectors currently in use
are replication competent or defective Adenoviruses, Canarypox
(ALVAC), and Vaccinia (NYVAC, MVA) (Franchini et al., 2004;
Gomez et al., 2008; Patterson and Robert-Guroff, 2008; Barouch,
2010; Chen et al., 2010; Rollier et al., 2011; Weli and Tryland,
2011). Adenoviruses, by targeting mucosal epithelium, induce
mucosal as well as systemic immunity. In fact, replication-
competent Adenovirus vectors display a broad biodistribution.
Regardless of mucosal immunization route, they target and
persist in macrophages and myeloid dendritic cells (Patterson
et al., 2012) and elicit comparable immune responses systemi-
cally and mucosally (Xiao et al., 2012). An interesting approach
is the use of recombinant Cytomegalovirus (CMV) vectors.
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These recombinants also persist in the host and stimulate strong
CD4 and CD8 cell responses (Hansen et al., 2011). Using
rhesus CMV vectors expressing SIV transgenes, strong pro-
tection from acquisition of SIVmac239 was achieved in a rec-
tal low-dose challenge model (Hansen et al., 2011). In spite
of the impressive protection in rhesus macaques, translation
into the clinic may present a challenge due to the signifi-
cant morbidity that can be caused by reoccurring CMV infec-
tion, seen for example, in immunosuppressed individuals (Sellar
and Peggs, 2012). Other vectors targeting the mucosa include
integrase-defective lentiviruses (Negri et al., 2011), noroviruses
(Herbst-Kralovetz et al., 2010) and engineered bacteria such
as Listeria, Salmonella, Lactococcus, and Lactobacillus (Shahabi
et al., 2010; Bahey-El-Din and Gahan, 2011; Lagenaur et al.,
2011).
DNA vaccines alone can also successfully prime and boost the
immune system (Ferraro et al., 2011; Sardesai and Weiner, 2011)
and together with viral vectors have induced lasting immune
responses and long-term control of virus infection following chal-
lenge of non-human primates (Patel et al., 2010; Lai et al., 2011;
Manrique et al., 2011; Winstone et al., 2011). Electroporation,
instead of intramuscular injection of DNA, has enhanced devel-
opment of durable immunity (Patel et al., 2010). Moreover, use
of DNA vaccines facilitates incorporation of cytokine immune
modulators (IL-15, IL-12, GM-CSF, and TNF-α) into the vaccine
strategy (Demberg et al., 2008; Ferraro et al., 2011; Lai et al., 2011;
Manrique et al., 2011; Winstone et al., 2011).
Vectored vaccines are often combined with envelope protein
boosts, requiring an adjuvant. Cytokines and TLR ligands can
serve this purpose (Berzofsky et al., 2001; Tovey and Lallemand,
2010; Bode et al., 2011; Duthie et al., 2011) but traditionally,
adjuvants function as depots while also acting as immunostim-
ulants (Reed et al., 2009; Carter and Reed, 2010). Currently
there are only two adjuvants in licensed vaccines available in
the USA: aluminum salts, including aluminum hydroxide, alu-
minum phosphate and alum (potassium aluminum sulfate);
and AS04 (aluminum hydroxide combined with monophos-
phoryl lipid (http://www.fda.gov/BiologicsBloodVaccines/Safety
Availability/VaccineSafety/ucm187810.htm). In Europe, addi-
tional approved adjuvants include MF59 (squalene-based oil in
water emulsion) and AS03 (also squalene-based) (Tritto et al.,
2009; Carter and Reed, 2010; O’Hagan et al., 2011). Yet addi-
tional adjuvants are needed. Broad new candidates include
carbohydrate-based and saponin based compounds, ISCOM
Matrix, cationic liposomes, and Nano-microparticles (Oyewumi
et al., 2010; Christensen et al., 2011; Lovgren Bengtsson et al.,
2011; Petrovsky and Cooper, 2011; Ragupathi et al., 2011; Schijns
and Lavelle, 2011).
A crucial aspect for the evaluation of candidate vaccines
is availability of relevant animal models. Currently there are
only two appropriate models: non-human primates and the
newly developed bone marrow/liver/thymus (BLT) mouse model.
The BLT mouse develops human T cells and B cells, mono-
cyte/macrophages and DC (Wege et al., 2008). In this model HIV
latency has been described and thus the BLT mouse is suitable for
testing drug regimens, including evaluation of HDAC inhibitors
(Marsden et al., 2011). Due to the reconstitution of the female
BLT mouse reproductive tract with human immune cells, vaginal
challenges can be performed and microbicides can be evaluated
(Denton et al., 2011; Olesen et al., 2011). In addition, candidate
vaccines based on non-replicating vectors as well as novel adju-
vants can be tested in a shorter time frame and at lower cost
compared to non-human primate models (Biswas et al., 2011).
However, the BLT mouse model has its limitations, including
lack of proper T-cell help which affects development of humoral
responses (Biswas et al., 2011).
Overall non-human primates provide the best, although not
perfect, model for evaluation of pre-clinical candidate vaccines
(Morgan et al., 2008; Rompay, 2011). The SIV rhesus macaque
system appropriately models HIV disease of humans with regard
to mode of transmission, viremia levels, depletion of CD4 cells,
and development of AIDS. However, the difference in the SIV
and HIV envelopes does not allow evaluation of anti-HIV enve-
lope immunity in the SIV system. The SHIV model while not
as robust, allows evaluation of vaccines targeting the HIV enve-
lope and their ability to elicit sterilizing immunity, however,
it is generally poorly pathogenic and overall a poor model of
HIV biology and disease progression in humans. Further, experi-
ments in non-human primates are expensive, and the number of
macaques required for a pre-clinical vaccine study has increased
with the use of low-dose repeated challenge experiments that
better mimic the HIV infection of people (Keele et al., 2009).
Thus, evaluation of a single vaccine candidate and a control could
require 50 macaques (Hudgens and Gilbert, 2009), However, it
could be designed and completed quickly. The cost for such a
macaque study is far surpassed by that of a human clinical trial.
As summarized by Shedlock et al. (2009), the non-human pri-
mate model has a key role to play in evaluating vaccine candidates
for the ability to induce improved immune responses, in test-
ing hypothesis driven research, in providing proof of concept,
and in identifying new immune targets for incorporation into
vaccine design. In that way the model helps select vaccine can-
didates for advancement into the limited number of possible
clinical trials.
SUMMARY AND CONCLUSION
As briefly summarized by this review the substantial progress
made in AIDS treatment has stimulated the concept of “treatment
as prevention.” Additionally, vaccine development has picked up
momentum due to new discoveries and the modest success of the
RV144 clinical trial in Thailand. However, to achieve global con-
trol of HIV/AIDS infection in the absence of a highly efficacious
vaccine or cure, a combination of multiple preventive measures
will need to be continuously applied. Further investigation of all
elements of the host immune system, both innate and adaptive,
as well as development of novel treatment strategies should pro-
ceed in order to insure strong control of the AIDS pandemic and
eventual eradication of the disease.
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